The circular RNA circPTK2 inhibits EMT in hepatocellular carcinoma by acting as a ceRNA and sponging miR-92a to upregulate E-cadherin
The circular RNA circPTK2 inhibits EMT in hepatocellular carcinoma by acting as a ceRNA and sponging miR-92a to upregulate E-cadherin
复制标题
环状 RNA circPTK2 通过充当 ceRNA 并海绵 miR-92a 上调 E-cadherin 来抑制肝细胞癌中的 EMT
DOI：
10.26355/eurrev_202009_23014
复制
发表时间：
2020-01-01
影响因子：
3.3
通讯作者：
Shan, H.
中科院分区：
文献类型：
--
作者：
Gong, T-T;Sun, F-Z;Shan, H.
【摘要】：目的:肝细胞癌(HCC)是一种常见的恶性肿瘤。越来越多的证据表明 microRNA (miRNA) 在多种细胞过程中发挥着重要作用。然而，关于 miRNA 在 HCC 中的作用和潜在分子机制的报道很少。 患者和方法：进行 qRT-PCR 和蛋白质印迹来量化 miR-92a、E-cadherin 和 circPTK2 的表达。进行增殖和侵袭测定以探索 miR-92a 和 circPTK2 的功能。使用荧光素酶测定来测试 miR-92a、E-cadherin 和 circPTK2 之间的关系。 结果：在这项研究中，我们发现 miR-92a 在 HCC 组织和 HCC 细胞系中表达上调。 miR-92a 的过表达通过靶向 HCC 细胞中的 E-钙粘蛋白 3'UTR 来增强细胞增殖和侵袭。此外，我们发现 circPTK2 通过抑制 miR-92a 来抑制 EMT，从而阻止其下调 HCC 细胞中 E-钙粘蛋白的能力。结论：我们在 HCC 细胞中鉴定了一个包含 circPTK2/miR-92a/E-cadherin 的调节轴，该轴可能作为 HCC 患者有价值的生物标志物和治疗靶点。
OBJECTIVE: Hepatocellular carcinoma (HCC) is a common malignant tumor. Increasing evidence has demonstrated that microRNAs (miRNAs) play an important role in a wide variety of cellular processes. However, there are few reports about the role and underlying molecular mechanisms of miRNAs in HCC.PATIENTS AND METHODS: qRT-PCR and Western blots were performed to quantify the expression of miR-92a, E-cadherin, and circPTK2. Proliferation and invasion assays were performed to explore the function of miR-92a and circPTK2. A Luciferase assay was used to test the relationship between miR-92a, E-cadherin, and circPTK2.RESULTS: In this study, we found that miR-92a was upregulated in HCC tissues and HCC cell lines. Overexpression of miR-92a enhanced cell proliferation and invasion by targeting the E-cadherin 3'UTR in HCC cells. Furthermore, we found that circPTK2 inhibited EMT by inhibiting miR-92a, preventing its ability to downregulate E-cadherin in HCC cells.CONCLUSIONS: We identified a regulatory axis comprising circPTK2/miR-92a/E-cadherin in HCC cells that may serve as a valuable biomarker and therapeutic target for patients with HCC.